Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155216 | 0.80 | NPC1 (0.56) | NPC1RAB9ALMNAKMT2AMAPK1 | |
| SCHEMBL18625 | 0.79 | NPC1 (0.47) | NPC1RAB9AARLMNAKMT2A | |
| SCHEMBL9367643 | 0.77 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3SLC22A12AR | |
| SCHEMBL17085521 | 0.77 | KDM4E (0.41) | SLC6A4SLC6A2SLC6A3NPC1RAB9A | |
| SCHEMBL22904596 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3SLC22A12AR | |
| SCHEMBL22169493 | 0.74 | RAB9A (0.47) | RAB9AARGAAKMT2AL3MBTL1 | |
| SCHEMBL14861296 | 0.74 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2SLC22A12 | |
| SCHEMBL22904395 | 0.74 | RHEB (0.44) | SLC6A4SLC6A2SLC6A3SLC22A12LMNA | |
| SCHEMBL2881518 | 0.74 | AR (0.42) | SLC6A4SLC6A2SLC6A3KCNH2SLC22A12 | |
| SCHEMBL22169453 | 0.74 | POLB (0.57) | SLC6A4SLC6A2SLC6A3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2514748-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A2 931/4885SLC6A3 1143/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A2 931/4885SLC6A3 1143/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A2 931/4885SLC6A3 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.